ImmunoVaccine (OTCQX:IMMVF; TSX:IMV) appointed Dr. Gabriela Rosu, as the company's first chief medical officer, effective Nov. 7, to lead the clinical efforts to develop the company's DepoVax-based product candidates in immuno-oncology and infectious diseases.
"The clinical and commercial experience that Gabriela brings to our team will be instrumental in preparing for our expansion and validates the potential of our platform and product candidates,” CEO, Frederic Ors, said in a statement.
Dr. Rosu brings to Immunovaccine more than 15 years of broad clinical and pharmaceutical industry experience, spanning early-phase discovery to post-marketing commercialization.
Most recently, she was medical science liaison, hematology oncology, at Janssen, where she was responsible for the regional medical strategy implementation for targeted and immuno-modulating therapy in chronic lymphocytic leukemia and multiple myeloma. She also has served as global medical advisor in hematology at Novo Nordisk.
Dr. Rosu said Immunovaccine is a pioneer in immuno-oncology, initiating one of the first combination trials in the field in 2011, when immuno-oncology was still in its infancy.
“Today, we understand much more clearly how our immune system has the ability to battle cancers when we can program it with the right instructions,” she added. “Immunovaccine has developed what I believe to be among the most promising technology and product candidates to achieve just that.”